Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma

NCT04421378 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT04421378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04421378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
June 8, 2020
Completion date
July 3, 2023
Enrollment
74 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme